Today was one of the most anticipated days in Spain since the vaccination campaign began: the first doses of the Janssen vaccine, from Johnson & Johnson, are beginning to arrive, long-awaited because it requires a single dose for complete vaccination and assumes in practice a cut in half of administrations necessary to get people immunized.
However, just on the day those first consignments of Janssen vials arrive in Spain, news can fall like a jug of cold water: the Center for Biological Evaluation and Research of the United States Food and Drug Administration has asked to pause the administration of this vaccine after detecting that six of the people who have received it in recent weeks have developed a disorder linked to blood clots. Six cases out of 6.8 million vaccinated.
A piece of news that reminds us of what happened with the AstraZeneca vaccine, which will no longer be inoculated in Spain to children under 60 years of age. It remains to be expected if the US government makes a firm decision in the next few hours after this health recommendation.
